Publication Abstract from PubMed
Nelfinavir is an inhibitor of HIV-1 protease, and is used for treatment of patients suffering from HIV/AIDS. However, treatment results in drug resistant mutations in HIV-1 protease. N88D and N88S are two such mutations which occur in the non-active site region of the enzyme. We have determined crystal structures of unliganded N88D and N88S mutants of HIV-1 protease to resolution of 1.65A and 1.8A, respectively. These structures refined against synchrotron data lead to R-factors of 0.1859 and 0.1780, respectively. While structural effects of N88D are very subtle, the mutation N88S has caused a significant conformational change in D30, an active site residue crucial for substrate and inhibitor binding.
Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.,Bihani SC, Das A, Prashar V, Ferrer JL, Hosur MV Biochem Biophys Res Commun. 2009 Nov 13;389(2):295-300. Epub 2009 Aug 29. PMID:19720046[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
